Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.31 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.31 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1800727 | 0.73 | CCNT1 (0.30) | — | |
| SCHEMBL27048276 | 0.73 | CCNT1 (0.30) | — | |
| SCHEMBL17869465 | 0.73 | CHRNB2 (0.31) | — | |
| Hydrochloric Acid SCHEMBL8156603 | 0.71 | — | — | |
| SCHEMBL19431925 | 0.70 | CYP11B2 (0.66) | CYP11B1CYP11B2 | |
| SCHEMBL12265082 | 0.69 | SSTR4 (0.32) | — | |
| SCHEMBL29649416 | 0.68 | CYP11B1 (0.50) | CYP11B1CYP11B2PKMPOLBHTT | |
| SCHEMBL9869341 | 0.68 | POLB (0.38) | POLBKDM4EALDH1A1KMT2A | |
| SCHEMBL25274344 | 0.67 | CCNT1 (0.32) | — | |
| SCHEMBL30229307 | 0.67 | PARP1 (0.36) | CYP11B1CYP11B2PKMPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-9844553-B2 | Pyrazolopyridyl compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170020879-A1 | PYRAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2017-01-26 | — | — | US | disclosed |
| US-7179801-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-02-20 | — | — | US | disclosed |
| EP-1392704-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2006-02-22 | — | — | EP | disclosed |
| US-20040248875-A1 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1392704-A1 | CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002090364-A1 | CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-14 | — | — | WO | disclosed |
| US-4847256-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0264773-A1 | 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1988-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | BCKDK, CYP11B2, HSD17B7 | CYP11B1 4/4885CYP11B2 2/4885PKM 18/4885 |
| US-20170020879-A1 | PYRAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B2, CYP11B1 | CYP11B1 3/4885CYP11B2 2/4885PKM 297/4885 |
| US-20040248875-A1 | Cephem compounds | CEP170, C1S, SLC7A1 | CYP11B1 418/4885CYP11B2 443/4885PKM 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.